fig1
![Update on targeted therapy and immune therapy for gastric cancer, 2018](https://image.oaes.cc/3be17168-5502-4f6c-8118-a718fbdd8f1b/2638.fig.1.png)
Figure 1. Targeted therapy and oncogenic pathways in gastric cancer. EGFR: epidermal growth factor receptor; HER: humanepidermal growth factor receptor; HGF: hepatocyte growth factor; mTOR: mammaliantarget of rapamycin; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor